TransCode Therapeutics (RNAZ) Registration filing summary

Company overview and business model

• Clinical-stage company focused on immuno-oncology and RNA therapeutics for high-risk and advanced cancers, with a diversified pipeline including two clinical-stage assets and multiple preclinical programs.

• Lead programs include TTX-MC138 (antisense inhibitor of oncogenic microRNA) and Seviprotimut-L (cancer vaccine), as well as an oncolytic immunotherapy platform and TTX-based preclinical assets.

• Proprietary TTX drug design engine enables modular, customizable RNA delivery to tumors and metastases, supporting a range of RNA modalities and non-RNA payloads.

• Recent acquisitions and licensing agreements have expanded the pipeline to include oncolytic immunotherapy candidates and strategic collaborations.

Financial performance and metrics

• As of April 29, 2026, 916,968 shares of common stock were outstanding.

• The company qualifies as an emerging growth company and a smaller reporting company under federal securities laws.

• Audited financial statements for 2025 and 2024 include a going concern explanatory paragraph.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; proceeds go to selling stockholders.

• Responsible for certain offering fees and expenses related to registration.